Carlyle and SK Capital raise upfront offer in Bluebird Bio takeover bid
Carlyle Group and SK Capital Partners have increased the upfront portion of their takeover bid for gene therapy developer bluebird bio, to $5 per share in cash from $3 per share plus a contingent value right, according to a joint statement issued on Wednesday.
